

Carbapenem-Resistant *Acinetobacter* spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic

Maddalena Giannella,^{1,2,✉} Stefano Verardi,³ Andreas Karas,³ Hasania Abdel Hadi,⁴ Hervé Dupont,⁵ Alex Soriano,^{6,7} Anne Santerre Henriksen,³ Andrew Cooper,⁸ and Marco Falcone,^{9,✉} for the ARES Study Group

¹Infectious Diseases Unit, Istituto di Ricovero e Cura a Carattere Scientifico - Policlinico di Sant'Orsola, Bologna, Italy, ²Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy, ³Medical Affairs, Shionogi B.V., London, United Kingdom, ⁴Unidad de Cuidados Intensivos, Hospital General Universitario, Ciudad Real, Spain, ⁵Anesthesiology and Critical Care Medicine, Centre Hospitalier Universitaire d'Amiens Picardie, Amiens, France, ⁶Department of Infectious Diseases, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, ⁷Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Barcelona, Spain, ⁸Global Epidemiology and Real-World Evidence, Shionogi B.V., London, United Kingdom, and ⁹Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Background. Carbapenem-resistant *Acinetobacter baumannii* infections are difficult to treat and are a significant public health threat due to intrinsic/acquired resistance and limited treatment options.

Methods. A retrospective, observational cohort study in patients receiving cefiderocol via Shionogi's early access program for *Acinetobacter* spp infections (1 April 2020–30 April 2021; 27 sites; Italy, Spain, Germany, France). Primary outcome was clinical success, defined as clinical resolution of infection at day 14 or day 28 survival.

Results. Overall, 147 patients were included. Primary infection sites were respiratory (65.3%) and bloodstream (unknown source [15.6%]; catheter-related [10.9%]); 24.5% of patients had polymicrobial infection. Of 136 patients in intensive care (92.5%), 85.3% (116/136) received mechanical ventilation. Septic shock (55.6% [70/126]) and coronavirus disease 2019 (COVID-19) (81.6%) were prevalent. Prior to cefiderocol, 85.0% of patients received gram-negative treatment, 61.2% received ≥ 2 antimicrobials, and most received colistin (58.5%; median duration, 11.5 days). Cefiderocol monotherapy was used in 30.6% of patients. Clinical success rate was 53.1% and was higher in patients without septic shock (62.5%), without COVID-19 (77.8%), and with lower Sequential Organ Failure Assessment (SOFA) scores (quartile 1 [median, 3; range, 0–5]: 82.9%). Day 28 survival was 44.9% and was higher in patients without septic shock (60.7%), without COVID-19 (59.3%), with lower SOFA score (quartile 1: 82.9%), and receiving first-line cefiderocol (68.2% [15/22]). Resolution of infection at day 14 occurred in 39.5% of patients.

Conclusions. Despite use in complex patients with limited treatment options and high septic shock/COVID-19 rates, cefiderocol treatment was associated with an overall clinical success rate of 53%.

Keywords. COVID-19; *Acinetobacter*; cefiderocol; mortality; septic shock.

Carbapenem-resistant (CR) *Acinetobacter baumannii* (CRAB) infections are difficult to treat, and treatment options are limited due to intrinsic and acquired resistance to several antimicrobial classes [1, 2].

Infections due to CRAB have been increasingly prevalent in Europe in recent years [3–5] and are an independent risk factor for mortality [6]. In patients with CRAB infection, all-cause mortality rates range between 18% and 57%, which are generally higher than other World Health Organization critical priority gram-negative pathogens—CR Enterobacterales (12%–40%) and *Pseudomonas aeruginosa* (20%–31%) [7, 8]. The presence of septic shock and/or coronavirus disease 2019 (COVID-19) further increases the risk of mortality [9, 10]. Therefore, the need for new treatment options is becoming more urgent.

Cefiderocol is approved in Europe for the treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options. Per the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidance for treatment of CRAB infection, cefiderocol is conditionally not recommended; however, supporting evidence is

Received 11 April 2023; editorial decision 21 June 2023; accepted 03 July 2023; published online 4 July 2023

Correspondence: Maddalena Giannella, MD, PhD, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico di Sant'Orsola, Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 11, Bologna 40138, Italy (maddalena.giannella@unibo.it); Andreas Karas, MD, Medical Affairs, Shionogi B.V., 33 Kingsway, London WC2B 6UF, UK (andreas.karas@shionogi.eu).

Open Forum Infectious Diseases®

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

<https://doi.org/10.1093/ofid/ofad329>

recognized to be of low certainty [11, 12]. In contrast, according to Infectious Diseases Society of America (IDSA) guidance, ceftiderocol is recommended for patients in whom use of other antimicrobials is precluded [13]. Current treatment guidance for infection due to CRAB from ESCMID and IDSA conditionally recommend treatment regimens with ampicillin/sulbactam when susceptibility is demonstrated, although there is limited supporting evidence [11, 13]. Colistin may be considered for CRAB infection, according to ESCMID, but not without evidence of in vitro activity and the presence of sulbactam resistance [11]. European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidance states that colistin should not be used as monotherapy [14].

In the APEKS-NP and CREDIBLE-CR phase 3 studies, survival rates of 78% (18/23; vs 83% [20/24] with meropenem at day 14) and 51% (20/39; vs 82% [14/17] with best-available therapy at end of study), respectively, were reported for patients with CR *Acinetobacter* spp infection [15, 16]. Data from real-world experience suggest clinical effectiveness of ceftiderocol in patients with CR *Acinetobacter* spp infection [17–28]. Despite the limitation of an observational design, a recent study demonstrated that ceftiderocol-containing regimens are associated with higher survival rates compared with colistin-containing regimens in patients with bloodstream infection (BSI) due to CR *Acinetobacter* spp [27]. However, these findings were not confirmed in patients with COVID-19 and when ceftiderocol was used as monotherapy [28].

The aim of this study was to assess real-world evidence on the clinical characteristics, treatment effectiveness, and safety of ceftiderocol (supplied via the Shionogi early access program [EAP]) in patients with CR *Acinetobacter* spp infection in Europe.

METHODS

Data Collection

The ARES study was a retrospective, descriptive, observational cohort study in patients who received ceftiderocol via the Shionogi EAP for treatment of *Acinetobacter* spp infections between 1 April 2020 and 30 April 2021. The EAP was established by Shionogi B.V. in April 2020 to enable access to ceftiderocol in European countries where it was not yet available on the market. A total of 27 sites across 4 countries (Italy, Spain, Germany, and France) were identified from the Shionogi EAP database for inclusion. Selected sites requested ceftiderocol via the EAP for treatment of ≥ 1 patient(s) with a CR *Acinetobacter* spp infection.

Inpatient hospital medical records and laboratory reports were used for data extraction. Data recorded at the study site between hospital admission date and day 28 following ceftiderocol administration, or the date of discharge from the episode of hospitalization, whichever occurred sooner, were collected.

Patients ≥ 18 years of age hospitalized due to gram-negative infection (excluding central nervous system infection) with suspected (based on investigator opinion) or evident carbapenem resistance were included. Ceftiderocol susceptibility testing was not mandatory for EAP enrollment. Of the patients in the EAP database, the inclusion criterion for this study was ≥ 72 hours of ceftiderocol therapy received in hospital for *Acinetobacter* spp infection, following no prior use of ceftiderocol, either as a last-resort antibiotic or when no other alternative antibiotics were available. Patients with a gram-negative coinfection resistant to ceftiderocol within 14 days of initial ceftiderocol dose were excluded. The study included some patients treated for CR *Acinetobacter* spp with excess ceftiderocol stock from previous EAP requests, which was done at the discretion of the treating clinician (Nota bene, the product was licensed in Europe and was pending national reimbursement).

This study was conducted in compliance with guidance from the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (2015), International Society for Pharmacoepidemiology (2015), Council for International Organizations of Medical Sciences (2009), and European Medicines Agency (2020). Written patient consent was obtained prior to data extraction in accordance with local regulations; assumed consent was utilized in accordance with local regulations. If the patient was unable to provide consent, this was obtained through a family member or relative in accordance with local European Committee approvals and guidance or in line with local regulations.

Outcomes, Variables, and Definitions

The primary outcome was clinical success in patients with CR *Acinetobacter* spp infection treated with ceftiderocol. Clinical success was a composite endpoint defined as clinical resolution of investigator-assessed signs and symptoms of *Acinetobacter* spp infection at day 14, or survival at day 28 following first ceftiderocol dose. Clinical resolution of signs and symptoms was defined as the cessation of ceftiderocol treatment due to improvement in symptoms of infection.

Secondary outcomes included (1) survival at day 14 and day 28; (2) clinical outcomes of ceftiderocol treatment; and (3) safety. Mortality at day 14 was imputed as treatment failure regardless of the cause of death. Clinical outcomes included (1) resolution of investigator-assessed signs and symptoms of *Acinetobacter* spp infection at day 7 and day 14 (excludes patients with improved symptoms); (2) treatment failure at day 7 and day 14; and (3) relapse of primary *Acinetobacter* spp infection (isolation of the same *Acinetobacter* spp ≤ 30 days after end of ceftiderocol treatment). Safety data were adverse drug reactions (ADRs, treatment-related adverse events [AEs]); total AEs (not necessarily with a causal relationship with the treatment) were not included.

Additional variables extracted included (1) patient characteristics, including clinical characteristics of CR *Acinetobacter*

spp infection (mono- and polymicrobial infections), septic shock (yes/no) at time of cefiderocol initiation and/or COVID-19 status (positive/negative) during hospitalization, severity of illness at time of cefiderocol initiation (by Sequential Organ Failure Assessment [SOFA] score), and treatment for CR *Acinetobacter* spp infection prior to cefiderocol use; and (2) cefiderocol treatment characteristics (monotherapy/combination therapy). SOFA scores of 0 were imputed for individual SOFA domains where data were missing, providing a value was recorded for at least 1 of the 6 SOFA domains. Septic shock was defined as a score of 3 or 4 on the SOFA score cardiovascular domain, describing patients who received dopamine, epinephrine, or norepinephrine [29, 30]. Combination therapy was defined as use of an antibiotic generally used for treatment of CRAB, in conjunction with cefiderocol.

Survival probability curves were analyzed based on recorded dates of cefiderocol initiation and death.

Descriptive analyses for continuous variables were reported as median and interquartile, minimum, and maximum ranges; categorical variables were reported as frequency and percentage.

RESULTS

Study Population

A total of 227 EAP patient requests for the use of cefiderocol for *Acinetobacter* spp infection were received during the study period. Of 156 patients screened, 147 were included for analysis (Figure 1). The median age of patients was 62 (interquartile range [IQR], 53–71) years and 78.9% (116/147) were male;

78.9% (116/147) of hospital admissions were emergency admissions (91.2% [134/147]) (Table 1).

Infection

Of the 147 patients included, 146 had *A baumannii* infection and 1 had an infection defined as “*Acinetobacter*–other.” Primary infection sites were respiratory (65.3% [96/147]), BSI (unknown source, 15.6% [23/147]; catheter related, 10.9% [16/147]), and other (8.2% [12/147]) (Table 1). Secondary BSIs with *Acinetobacter* spp occurred in 32.0% (47/147) of patients. Polymicrobial gram-negative infections were reported in 24.5% (36/147) of patients (Table 1; Supplementary Table 1), while gram-positive pathogens were isolated from 18.4% (27/147) of patients.

Most patients (92.5% [136/147]) spent some time in an intensive care unit (ICU) during hospitalization with a median length of total ICU stay of 37 (IQR, 23.5–51.0) days (Table 1). Of 136 patients in the ICU, 85.3% (116/136) received mechanical ventilation (Table 1). Of 96 patients with respiratory infection, 85.4% (82/96) received mechanical ventilation; of these 85.4% (70/82) had ventilator-associated pneumonia (VAP), 13.4% (11/82) had ventilated hospital-acquired pneumonia (V-HAP), and 1.2% (1/82) had undefined respiratory infection (Table 1).

Patient Status and Comorbidities

A high proportion of patients (55.6% [70/126]) had septic shock at time of cefiderocol initiation, and most (81.6% [120/147]) had COVID-19 during hospitalization; 39.5% (58/147) had both septic shock and COVID-19 (Table 1).

SOFA scores were reported for 96.3% (131/136) of patients who spent time in ICU (Table 1). To analyze outcomes in




Figure 1. Flowchart of patient record selection from screening of the early access program database. Abbreviations: CR, carbapenem-resistant; EAP, early access program.

Table 1. Patient and Clinical Characteristics (N = 147)

Characteristic	No. (%)
Patient characteristics	
Age, y, median (range; IQR)	62 (23–82; 53–71)
Sex	
Female	31 (21.1)
Male	116 (78.9)
Hospital admission	
Emergency	134 (91.2)
Scheduled	9 (6.1)
Other	4 (2.7)
Infection	
Site of primary infection	
Respiratory	96 (65.3)
BSI (catheter related)	16 (10.9)
BSI (unknown source)	23 (15.6)
Other ^a	12 (8.2)
Secondary BSI	47 (32.0)
Polymicrobial infection	36 (24.5)
ICU/ventilation	
Any time in ICU	136 (92.5)
Time in ICU, d, median (IQR)	37 (23.5–51.0)
In ICU receiving mechanical ventilation	116/136 (85.3)
Respiratory infection and receiving mechanical ventilation	82/96 (85.4)
Ventilator-associated respiratory infection	
VAP	70/82 (85.4)
V-HAP	11/82 (13.4)
Unknown ^b	1/82 (1.2)
ECMO during hospitalization	22 (15.0)
Patient status and comorbidities	
Septic shock ^c	70/126 (55.6)
COVID-19 during hospitalization	120 (81.6)
Septic shock ^c and COVID-19 during hospitalization	58 (39.5)
SOFA score ^d quartile (score range) in ICU, no./No. (median score)	
1 (0–5)	35/131 (3)
2 (6–9)	44/131 (8)
3 (10–11)	32/131 (11)
4 (12–17)	20/131 (13)
Treatment regimen	
No. of prior antimicrobial therapies ^e	
0	22 (15.0)
1	35 (23.8)
2	48 (32.7)
3	29 (19.7)
4	10 (6.8)
≥5	3 (2.0)
Prior antimicrobial therapy ^{e,f}	
Colistin	86 (58.5)
Meropenem	62 (42.2)
Tigecycline	40 (27.2)
Piperacillin/tazobactam	22 (15.0)
Ampicillin/sulbactam	13 (8.8)
Reason for discontinuation of prior antimicrobial therapy ^g	
Lack of resolution	65 (44.2)
New resistance	34 (23.1)
Adverse events	5 (3.4)

Table 1. Continued

Characteristic	No. (%)
Other	19 (12.9)
Duration of ceftiderocol treatment, d, median (IQR)	
	10.0 (8.0–15.0)
Ceftiderocol administered as monotherapy	
Septic shock ^c present	21/42 (50.0)
SOFA score ^d , median (IQR)	7.5 (3.0–9.0)
Ceftiderocol administered as combination therapy	
Septic shock ^c present	49/84 (58.3)
SOFA score ^d , median (IQR)	9.0 (7.0–11.0)
Antibiotic therapy started with ceftiderocol administration	
Colistin	27 (18.4)
Tigecycline	22 (15.0)
Fosfomycin	19 (12.9)
Meropenem	3 (2.0)
Ampicillin/sulbactam	2 (1.4)
Trimethoprim/sulfamethoxazole	2 (1.4)
Other	12 (8.2)

Data are from time of ceftiderocol initiation and are presented as No. (%) or no./No. (%) unless otherwise indicated.

Abbreviations: BSI, bloodstream infection; COVID-19, coronavirus disease 2019; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IQR, interquartile range; SOFA, Sequential Organ Failure Assessment; VAP, ventilator-associated pneumonia; V-HAP, ventilated hospital-acquired pneumonia.

^aIncluded other (n = 4), skin and soft tissue infections (n = 3), bone or joint infections (n = 2), intra-abdominal infections (n = 2), and urinary tract infection (n = 1).

^bUnknown time of mechanical ventilation initiation.

^cSeptic shock was defined as a score of 3 or 4 on the cardiovascular domain on the SOFA score.

^dSOFA scores of 0 were imputed for individual SOFA domains where data were missing, providing a value was recorded for at least 1 of the 6 SOFA domains.

^eTherapies suitable for gram-negative infections used to treat *Acinetobacter* spp infections.

^fFive most frequently used antimicrobials are shown. Patients may have received ≥1 antimicrobial prior to ceftiderocol.

^gReasons per prior antimicrobial are shown.

patients according to severity of illness, SOFA scores were divided into quartiles. At time of ceftiderocol initiation, 35 patients were in SOFA score quartile 1 (median score, 3 [range, 0–5]), 44 in quartile 2 (median, 8 [range, 6–9]), 32 in quartile 3 (median, 11 [range, 10–11]), and 20 in quartile 4 (median, 13 [range, 12–17]) (Table 1). Median SOFA scores were 10 (range, 3–17; IQR, 9–11) in patients with septic shock and 5 (range, 1–14; IQR, 3–8.5) in patients without septic shock (Supplementary Table 2).

During hospitalization, 15.0% (22/147) of patients received extracorporeal membrane oxygenation (Table 1).

Treatment Regimens

Prior to ceftiderocol initiation, 61.2% (90/147) of patients received ≥2 gram-negative antimicrobials (Table 1). Colistin-based therapy was administered in 58.5% (86/147) of patients with a median (IQR) treatment duration of 11.5 (6.0–18.0) days (Supplementary Tables 3 and 4). Median (IQR) treatment durations of prior ampicillin/sulbactam and tigecycline treatment were 8.0 (7.0–10.0) days and 15.0 (9.0–20.0) days,

Table 2. Primary and Secondary Outcomes (N = 147)

Outcome	No. (%) [95% CI]
Overall clinical success	78 (53.1) [45.0–61.1]
Overall assessment of clinical benefit of cefiderocol at day 14	
Resolution of infection	58 (39.5) [31.6–47.4]
Improved symptoms	18 (12.2) [7.0–17.5]
Unable to determine	11 (7.5) [3.2–11.7]
Failure ^a	56 (38.1) [30.2–46.0]
Missing	4 (2.7) [1.1–5.4]
Survival at day 28	
Alive	66 (44.9) [36.9–52.9]
Deceased	75 (51.0) [42.9–59.1]
Unknown	5 (3.4) [1.5–6.3]
Missing data	1 (0.7) [–.7 to 2.0]
Resolution of infection at day 14 and survival at day 28	46 (31.3) [23.8–38.8]
Clinical success according to infection	
Monomicrobial infection	58/111 (52.3) [43.0–61.5]
Polymicrobial infection	20/36 (55.6) [39.3–71.8]
Site of infection	
Respiratory	44/96 (45.8) [35.9–55.8]
BSI (catheter related)	12/16 (75.0) [53.8–96.2]
BSI (unknown source)	12/23 (52.2) [31.8–72.6]
Other ^b	10/12 (83.3)
Ventilator-associated respiratory infection	
VAP	31/70 (44.3) [32.7–55.9]
V-HAP	4/11 (36.4) [7.9–64.8]
Unknown ^c	1/1 (100.0)
Clinical success according to patient status and comorbidities	
Septic shock ^d present	26/70 (37.1) [25.8–48.5]
Septic shock ^d absent	35/56 (62.5) [49.8–75.2]
COVID-19 present	57/120 (47.5) [38.6–56.4]
COVID-19 absent	21/27 (77.8) [62.1–93.5]
Septic shock ^d present, COVID-19 present	18/58 (31.0)
SOFA score ^e quartile	
1 (median, 3 [range, 0–5])	29/35 (82.9) [70.4–95.3]
2 (median, 8 [range, 6–9])	19/44 (43.2) [28.6–57.8]
3 (median, 11 [range, 10–11])	12/32 (37.5) [20.7–54.3]
4 (median, 13 [range, 12–17])	5/20 (25.0) [6.0–44.0]
Clinical success according to treatment regimen	
Monotherapy	30/49 (61.2) [47.6–74.9]
Combination therapy	48/98 (49.0) [39.1–58.9]
Cefiderocol as first-line therapy	15/22 (68.2)
Survival according to key mortality risk factors	
At day 28	
Septic shock ^d present	17/70 (24.3)
Septic shock ^d absent	34/56 (60.7)
COVID-19 present	50/120 (41.7)
COVID-19 absent	16/27 (59.3)
Survival according to treatment regimen	
At day 14	95/147 (64.6)
Monotherapy	33/49 (67.3)
Combination therapy	62/98 (63.3)
Cefiderocol as first-line therapy	16/22 (72.7)
At day 28	66/147 (44.9)
Monotherapy	26/49 (53.1)
Combination therapy	40/98 (40.8)

Table 2. Continued

Outcome	No. (%) [95% CI]
Cefiderocol as first-line therapy	15/22 (68.2)

Data are presented as No. (%) or no./No. (%), with [95% CI] where available.
Abbreviations: BSI, bloodstream infection; CI, confidence interval; COVID-19, coronavirus disease 2019; SOFA, Sequential Organ Failure Assessment; VAP, ventilator-associated pneumonia; V-HAP, ventilated hospital-acquired pneumonia.
^aMortality at day 14 was imputed as treatment failure, regardless of the cause of death.
^bIncluded other infections (4/4), skin and soft tissue infection (3/3), bone and joint infection (2/2), intra-abdominal infection (1/2), and urinary tract infection (0/1).
^cUnknown time of mechanical ventilation initiation.
^dSeptic shock was defined as a score of 3 or 4 on the cardiovascular domain on the SOFA score at time of cefiderocol initiation.
^eSOFA scores of 0 were imputed for individual SOFA domains where data were missing, providing a value was recorded for at least 1 of the 6 SOFA domains.

respectively (Supplementary Table 4). Reasons for discontinuation of antimicrobials prior to cefiderocol initiation included lack of resolution (44.2% [65/147]), new resistance (23.1% [34/147]), and AEs (3.4% [5/147]) (Table 1).

Median (IQR) duration of cefiderocol treatment was 10.0 (8.0–15.0) days, and it was used as first-line therapy in 15.0% (22/147) of patients. Cefiderocol was administered as monotherapy (33.3% [49/147]) and in combination with other antimicrobials, including colistin (18.4% [27/147]), tigecycline (15.0% [22/147]), and fosfomycin (12.9% [19/147]) (Table 1). In patients receiving cefiderocol monotherapy versus combination therapy, septic shock was present in 50.0% (21/42) versus 58.3% (49/84), and median (IQR) SOFA scores at time of cefiderocol initiation were 7.5 (3.0–9.0) versus 9.0 (7.0–11.0), respectively.

Primary Outcome

Clinical success rate in patients treated with cefiderocol was 53.1% (78/147) (Table 2). Rate of resolution of infection at day 14 was 39.5% (58/147) and survival at day 28 was 44.9% (66/147) (Table 2). In total, 31.3% (46/147) of patients had both resolution of infection at day 14 and were alive at day 28 (Table 2).

By Infection

Patients with monomicrobial infections (52.3% [58/111]) had similar clinical success to those with polymicrobial infections (55.6% [20/36]) (Table 2). By primary infection site, clinical success was 45.8% (44/96) in patients with respiratory infection, 52.2% (12/23) with BSI from an unknown source, and 75.0% (12/16) with catheter-related BSI (Table 2). Clinical success was 44.3% (31/70) in patients with VAP and 36.4% (4/11) in patients with V-HAP (Table 2).

By Patient Status and Comorbidities

Clinical success was 62.5% (35/56) in patients without septic shock versus 37.1% (26/70) with septic shock, and 77.8% (21/27) in patients without COVID-19 versus 47.5% (57/120)

with COVID-19 (Table 2). Where both septic shock and COVID-19 were present, clinical success was 31.0% (18/58) (Table 2). A small number of patients were without either septic shock or COVID-19, and clinical success in this subset was 71.4% (5/7).

Clinical success was higher in patients with lower SOFA scores: 82.9% (29/35) in SOFA quartile 1 (range, 0–5), 43.2% (19/44) in quartile 2 (range, 6–9), 37.5% (12/32) in quartile 3 (range, 10–11), and 25.0% (5/20) in quartile 4 (range, 12–17) (Table 2).

By Treatment Regimen

Of patients treated with cefiderocol as first-line therapy, 68.2% (15/22) achieved clinical success. Additionally, clinical success

was higher in patients receiving monotherapy (61.2% [30/49]) versus combination therapy (49.0% [48/98]) (Table 2).

Clinical success rates by time from *Acinetobacter* spp isolation to cefiderocol initiation are reported in Supplementary Table 5.

Secondary Outcomes

Survival Rate

Survival rate was 64.6% (95/147) at day 14 and 44.9% (66/147) at day 28 (Table 2; Figure 2A). Notably, survival rates at day 14 and day 28 for patients treated with cefiderocol as first-line therapy were 72.2% (16/22) and 68.2% (15/22), respectively (Table 2).




Figure 2. Kaplan-Meier survival rates up to day 28 (n = 147). Survival probability curves were analyzed based on recorded dates of cefiderocol initiation and death. There may be discrepancies between these recorded dates and the deaths registered at day 28 in the case report form. A, Total population. B, By presence/absence of septic shock. C, By presence/absence of coronavirus disease 2019 (COVID-19). D, By Sequential Organ Failure Assessment (SOFA) score quartiles. Septic shock was defined as a score of 3 or 4 on the cardiovascular domain on the SOFA score at time of cefiderocol initiation. SOFA scores of 0 were imputed for individual SOFA domains where data were missing, providing a value was recorded for at least 1 of the 6 SOFA domains.

Rate of survival at day 28 was higher both in patients without septic shock (60.7% [34/56]) versus those with septic shock (24.3% [17/70]) and in patients without COVID-19 (59.3% [16/27]) versus those with COVID-19 (41.7% [50/120]) (Table 2; Figure 2B and 2C). Additionally, rate of survival at day 28 was markedly higher in patients with lower SOFA scores (quartile 1, 82.9% [29/35]) versus those with higher scores (quartile 2, 34.1% [15/44]; quartile 3, 28.1% [9/32]; quartile 4, 10.0% [2/20]) (Figure 2D).

Clinical Benefit

At day 14, resolution of infection occurred in 39.5% (58/147) of patients, and treatment failure was recorded in 38.1% (56/147) (Table 2). At day 7, resolution of infection was reported in 19.0% (28/147) of patients and treatment failure in 15.0% (22/147) (Supplementary Table 6). Relapse of primary *Acinetobacter* spp infection occurred in 10.2% (15/147) of patients at a median (IQR) time of 10.0 (6.0–14.0) days following cefiderocol discontinuation.

Adverse Drug Reactions

Adverse drug reactions were reported in 4.8% (7/147) of patients, and 1.4% (2/147) experienced a total of 3 severe/serious ADRs (Table 3).

DISCUSSION

Determining the best treatment option for patients with severe illness previously treated with multiple antibiotics is challenging, as randomized controlled trials may not be feasible, so real-world experience is highly informative [31, 32]. This study provides a comprehensive collection of real-world evidence on cefiderocol as a therapeutic option for CR *Acinetobacter* spp infection in severely ill patients.

Table 3. Adverse Drug Reactions (N = 147)

ADR Classification	Patients, No. (%)	Events, No.
All ADRs	7 (4.8)	9
Mild	3 (2.0)	4
Pancytopenia	1 (0.7)	1
Hypernatremia	1 (0.7)	1
Rash	1 (0.7)	1
Hypertension	1 (0.7)	1
Moderate	1 (0.7)	1
<i>Clostridium difficile</i> colitis	1 (0.7)	1
Severe/serious ADRs	2 (1.4)	3
Cardiac arrest	1 (0.7)	1
Renal tubular necrosis	1 (0.7)	1
Tubulointerstitial nephritis	1 (0.7)	1
Not reported	1 (0.7)	1
Treatment withdrawal ^a	5 (3.4)	7

Abbreviation: ADR, adverse drug reaction.

^aTreatment withdrawals were assumed to be treatment related.

The primary outcome of clinical success in this study was lower with higher severity of illness, unsurprisingly. Overall clinical success was achieved in 53% of a population in which half of the patients had at least 1 key mortality risk factor, including septic shock (56%) or COVID-19 (82%), and 40% had both, with SOFA scores up to 17. The study period also encompassed the early phase of the COVID-19 pandemic, indicating that illness due to COVID-19 was likely severe. A high proportion of patients spent time in ICU (93%). Clinical success was higher in patients without septic shock (63%), without COVID-19 (78%), and with lower SOFA scores (83% in SOFA quartile 1), compared with the overall rate (53%).

The day 28 survival rate was also higher in patients without septic shock (61%) and lower in patients with septic shock (24%), compared with an overall survival rate of 45%. Previous studies have reported similar findings, with low survival rates in patients with septic shock and VAP caused by *A baumannii* (19% [31/159] and 23% [13/57], respectively) [9, 33, 34]. Septic shock has been shown to be significantly associated with increased risk of all-cause mortality at day 30 in patients with *A baumannii* and *Klebsiella pneumoniae* infections (odds ratio, 23.41 [95% confidence interval {CI}, 8.66–63.31]; $P < .001$) [35]. In addition, Russo et al reported that survival was significantly lower in patients with septic shock due to multidrug-resistant (MDR) *A baumannii* than with septic shock due to *K pneumoniae* carbapenemase-producing *K pneumoniae* (15% [14/92] vs 55% [71/128], respectively; $P < .001$) [10]. A baseline survival rate of 67% has been reported in patients with COVID-19 in European ICUs [36]; in this study, day 28 survival rates in patients with (42%) and without (59%) COVID-19 indicate that COVID-19 may have played a role in decreasing survival. These survival rates were higher than in a previous study in patients with COVID-19 and coinfection with *Acinetobacter* spp (14% [3/21]), albeit this was reported in a small population treated with a range of different therapies (not including cefiderocol) [9].

Day 28 survival (45% [66/147]) in the ARES population was broadly similar to previous observations in real-world case series in patients with CRAB infection by Falcone et al [27] (66% [31/47]), Pascale et al [28] (45% [19/42]), and Bavaro et al [17] (70% [7/10]). A number of patients (88% [87/99]) in these case series were treated via the Shionogi EAP and are included in the ARES patient set [17, 27, 28]. The observational comparative study by Falcone et al reported a higher survival rate with cefiderocol-containing regimens (66% [31/47]) versus colistin (44% [34/77]) ($P = .018$), whereas Pascale et al did not find cefiderocol to be associated with a significant lower risk of mortality versus colistin (survival, 45% [19/42] vs 42% [27/65]; hazard ratio, 0.64 [95% CI, .38–1.08]; $P = .10$) [27, 28]. Despite the different study designs, the survival rate of 45% that we observed in ARES is similar to that observed in the CREDIBLE-CR phase 3 study (50% [21/42]) in patients

receiving ceftiderocol for *Acinetobacter* spp infection (only 26% [11/42] had septic shock) [16].

Infection by CRAB is difficult to treat [1], and there is a lack of evidence of optimal clinical effectiveness of antimicrobial therapies, such as carbapenems, polymyxins, and tigecycline. This lack of evidence is reflected in treatment guidance, where recommendations tend to be conditional or weak [11, 13]. Additionally, colistin is not recommended as monotherapy by EUCAST or associated with a EUCAST breakpoint [14, 37]. In this study, the vast majority of patients (85%) received and failed on ≥ 1 prior antimicrobial commonly used against *Acinetobacter* spp infections, demonstrating the difficulty in treating such infections and the need for more effective therapy. Reflective of the current treatment landscape, prior therapy included >10 different agents, comprising a high proportion of colistin use (59%). Use of ampicillin/sulbactam (9%), recommended for treatment of CRAB in current ESCMID guidance, was low; however, the time period from which study data were collected predates these latest guidance [11]. Given the rate of clinical success demonstrated in this severe population, it is important that new treatments for CRAB infection such as ceftiderocol are considered, not just following treatment failure, especially when offering the potential for positive patient outcomes.

When ceftiderocol was used as first-line therapy (22/147), clinical success (68% [15/22]) was higher than the overall success rate (53% [78/147]) (Table 2). Severity of disease does not account for this improvement, as median SOFA score in patients treated with first-line ceftiderocol was 6, aligned with SOFA score quartile 2, where clinical success was 43%. It should be noted that the survival rate in patients with first-line ceftiderocol use was higher compared with overall survival at day 14 (73% [16/22] vs 65% [95/147], respectively) and day 28 (68% [15/22] vs 45% [66/147], respectively) (Table 2). In this small and heterogeneous population of complex, critically unwell patients with competing risks for outcomes, we were unable to examine independent associations between time to ceftiderocol therapy and clinical outcomes. Future studies in larger homogenous populations are required to fully elucidate the benefit of earlier ceftiderocol treatment.

Our study has several limitations. Data indicating the reasons for why the 9 patients from the EAP were not included in the ARES population (ie, which criterion or criteria each patient did or did not meet) are not available. Due to the retrospective nature of the study, treatment data were also not always available for abstraction, so confounding of the association between ceftiderocol and outcomes cannot be ruled out. This included data on the administration of steroids or immune modulators, which can affect outcomes in patients with MDR *A baumannii* infection and COVID-19 [38]. Some missing/partial clinical status and mortality data were imputed; however, this process was conservative, assuming that patients

were less severely ill (low SOFA score) and that mortality at day 14 was due to treatment failure. This clinical outcome was assumed since additional clinical and biomarker data for subanalyses were not available, and the data would have otherwise included a high proportion of patients in whom resolution of infection was undetermined. This may have been due to the high incidence of COVID-19 (82%) in the study population, as it is challenging to confirm whether resolution of VAP is due to *Acinetobacter* spp infection or COVID-19 pneumonia. The definition of septic shock (use of noradrenaline or adrenaline) also overlaps with the clinical syndrome associated with COVID-19 [39]. The composite definition of clinical success differs from those previously used in clinical practice, which typically define clinical success as the achievement of ≥ 2 outcomes at a single timepoint [40–43]. ARES patients received ceftiderocol treatment under emergency supply via the EAP; therefore, the composite outcome in this study allowed for consideration of the timeframe in which the effectiveness of ceftiderocol treatment could be best assessed. Resolution of infection after 14 days of therapy could be considered, and day 28 survival enabled later deaths (likely due to underlying conditions in this severely ill population, rather than CR *Acinetobacter* spp infection) to be excluded. However, 7 patients with relapse of infection following day 14 were included in the subset who achieved clinical success. Long-term follow-up outcomes were not assessed as data were not collected outside each patient's hospitalization episode. Unfortunately, a lack of susceptibility testing on initial and subsequent isolates meant that development of resistance or changing resistance patterns could not be discerned.

CONCLUSIONS

This study included a patient population with limited remaining treatment options for CR *Acinetobacter* spp infection and high rates of septic shock and COVID-19; despite this, ceftiderocol treatment was associated with an overall clinical success rate of 53%. Further studies assessing ceftiderocol treatment in different clinical scenarios are warranted.

Supplementary Data

[Supplementary materials](#) are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Author contributions. All authors contributed toward data collection and analysis, drafting, and revision of the manuscript, and agree to be accountable for all aspects of the work.

Acknowledgments. The authors acknowledge Hannah James, MSc, of Ashfield MedComms, an Inizio Company, for medical writing support funded by Shionogi B.V. in accordance with Good Publication Practice (GPP3 and GPP 2022) guidelines. Thanks also go to Shionogi B.V.

employees Gill Ibbotson and Maria Oppia, who provided support in the conduct of the study. The authors thank members of the ARES Study Group for their work: Pierluigi Viale, Maddalena Giannella, Renato Pascale, Marco Falcone, Giusy Tiseo, Alessandra Bandera, Toussaint Muheberimana, Valeria Pastore, Alessandra Saracino, Davide Fiore Bavaro, Lidia Dalfino, Luca Guerra, Francesco Barchiesi, Ylenia Farinaccio, Chiara Temperoni, Giustino Parruti, Simona Coladonato, Giorgia Rapacchiale, Laurenzia Ferraris, Alessandro Meloni, Andrea Bruni, Eugenio Garofalo, Carlo Torti, Paolo Grossi, Emanuele Durante Mangoni, Alessia Massa, Fabiana D'Amico, Domenico Iossa, Arta Karruli, Novella Carannante, Marco Merli, Carlo Pallotto, Elena Maria Seminari, Samantha Sottotetti, Roberto Carbone, Stefania Casolari, Elisa Vanino, Francesco Cristini, Luigi Raumer, Gennaro De Pascale, Agnese di Chiaro, Lucia Cubattoli, Alessandro Bartoloni, Nicoletta Di Lauria, Mario Venditti, Alessandra Oliva, Rosario Cultrera, Hasania Abdel Hadi, Carmen Hidalgo Tenorio, David Pérez Torres, Isabel Canas-Pérez, Luis López-Urrutia Lorente, Montserrat Rodriguez, Barbara Balandin, Raphaël Lepeule, Dominic Wichmann, Christina König, and Dominik Jarczok.

Data availability. Data are available upon reasonable request from Shionogi B.V.

Financial support. This work was sponsored by Shionogi B.V., London, UK.

Potential conflicts of interest. M. G. has received honoraria for lectures, presentations, or speaker's bureaus from MSD, Shionogi, Pfizer, and Gilead, and for participation on a data safety monitoring board or advisory board from MSD and Pfizer. S. V., A. K., and A. C. are employees of Shionogi B.V. H. D. has received fees from Shionogi for conferences and expert advisory boards. A. S. has received honoraria for lectures and advisory boards from Pfizer, MSD, Shionogi, Menarini, and Gilead. A. S. H. is an employee of Maxel Consulting ApS (Jyllinge, Denmark) and is a contractor for Shionogi B.V. M. F. has received grants and/or speaker honoraria from MSD, Angelini, Shionogi, Pfizer, Gilead, Menarini, and Nordic Pharma. H. A. H. reports no potential conflicts of interest.

References

- World Health Organization. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. 2017. Available at: <https://apps.who.int/iris/handle/10665/311820>. Accessed 6 June 2023.
- European Centre for Disease Prevention and Control. Rapid risk assessment: carbapenem-resistant *Acinetobacter baumannii* in healthcare settings. 2016. Available at: <https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/8-Dec-2016-RRA-Acinetobacter%20baumannii-Europe.pdf>. Accessed 6 June 2023.
- Pascale R, Bussini L, Gaibani P, et al. Carbapenem-resistant bacteria in an intensive care unit during the coronavirus disease 2019 (COVID-19) pandemic: a multicenter before-and-after cross-sectional study. *Infect Control Hosp Epidemiol* 2022; 43:461–6.
- Gaibani P, Viciani E, Bartoletti M, et al. The lower respiratory tract microbiome of critically ill patients with COVID-19. *Sci Rep* 2021; 11:10103.
- O'Toole RF. The interface between COVID-19 and bacterial healthcare-associated infections. *Clin Microbiol Infect* 2021; 27:1772–6.
- Pascale R, Corcione S, Bussini L, et al. Non-fermentative gram-negative bloodstream infection in northern Italy: a multicenter cohort study. *BMC Infect Dis* 2021; 21:806.
- World Health Organization. 2019 antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline. 2019. Available at: <https://www.who.int/publications/i/item/9789240000193>. Accessed 6 June 2023.
- Lodise TP, Bassetti M, Ferrer R, et al. All-cause mortality rates in adults with carbapenem-resistant gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. *Expert Rev Anti Infect Ther* 2022; 20:707–19.
- Silva DL, Lima CM, Magalhães VCR, et al. Fungal and bacterial coinfections increase mortality of severely ill COVID-19 patients. *J Hosp Infect* 2021; 113: 145–54.
- Russo A, Giuliano S, Ceccarelli G, et al. Comparison of septic shock due to multidrug-resistant *Acinetobacter baumannii* or *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae* in intensive care unit patients. *Antimicrob Agents Chemother* 2018; 62:e02562-17.
- Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). *Clin Microbiol Infect* 2022; 28:521–47.
- Shionogi B.V. Fetcroja (cefiderocol) summary of product characteristics. 2023. Available at: https://www.ema.europa.eu/en/documents/product-information/fetcroja-epar-product-information_en.pdf. Accessed 6 June 2023.
- Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant *Acinetobacter baumannii*, and *Stenotrophomonas maltophilia* infections. *Clin Infect Dis* 2022; 74:2089–114.
- European Committee on Antimicrobial Susceptibility Testing. Colistin breakpoints guidance document 2022. 2022. Available at: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/Colistin_guidance_2022.pdf. Accessed 6 June 2023.
- Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis* 2021; 21:213–25.
- Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. *Lancet Infect Dis* 2021; 21:226–40.
- Bavaro DF, Belati A, Diella L, et al. Cefiderocol-based combination therapy for “difficult-to-treat” gram-negative severe infections: real-life case series and future perspectives. *Antibiotics (Basel)* 2021; 10:651.
- Oliva A, Ceccarelli G, De Angelis M, et al. Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant *Acinetobacter baumannii*. *J Glob Antimicrob Resist* 2020; 23:292–6.
- Falcone M, Tiseo G, Nicastrò M, et al. Cefiderocol as rescue therapy for *Acinetobacter baumannii* and other carbapenem-resistant gram-negative infections in intensive care unit patients. *Clin Infect Dis* 2021; 72:2021–4.
- Rose L, Lai L, Byrne D. Successful prolonged treatment of a carbapenem-resistant *Acinetobacter baumannii* hip infection with cefiderocol: a case report. *Pharmacotherapy* 2022; 42:268–71.
- Mabayoje DA, NicFhogartaigh C, Cherian BP, Tan MGM, Wareham DW. Compassionate use of cefiderocol for carbapenem-resistant *Acinetobacter baumannii* prosthetic joint infection. *JAC Antimicrob Resist* 2021; 3:i21–4.
- Dagher M, Ruffin F, Marshall S, et al. Case report: successful rescue therapy of extensively drug-resistant *Acinetobacter baumannii* osteomyelitis with cefiderocol. *Open Forum Infect Dis* 2020; 7:ofaa150.
- Trecarichi EM, Quirino A, Scaglione V, et al. Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR *Acinetobacter baumannii* and KPC-producing *Klebsiella pneumoniae*: a case report. *J Antimicrob Chemother* 2019; 74:3399–401.
- Cipko K, Kizny Gordon A, Adhikari S, Konecny P. Cefiderocol treatment of *Pseudomonas aeruginosa* and extensively drug-resistant *Acinetobacter baumannii* retained spinal hardware infection causing reversible acute interstitial nephritis: recto: cefiderocol causing acute interstitial nephritis. *Int J Infect Dis* 2021; 109: 108–11.
- Zingg S, Nicoletti GJ, Kuster S, et al. Cefiderocol for extensively drug-resistant gram-negative bacterial infections: real-world experience from a case series and review of the literature. *Open Forum Infect Dis* 2020; 7:ofaa185.
- Rando E, Segala FV, Vargas J, et al. Cefiderocol for severe carbapenem-resistant *Acinetobacter baumannii* pneumonia: towards the comprehension of its place in therapy. *Antibiotics (Basel)* 2021; 11:3.
- Falcone M, Tiseo G, Leonildi A, et al. Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2022; 66:e0214221.
- Pascale R, Pasquini Z, Bartoletti M, et al. Cefiderocol treatment for carbapenem-resistant *Acinetobacter baumannii* infection in the ICU during the COVID-19 pandemic: a multicenter cohort study. *JAC Antimicrob Resist* 2021; 3:d1ab174.
- Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA* 2016; 315:801–10.
- Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score—development, utility and challenges of accurate assessment in clinical trials. *Crit Care* 2019; 23:374.
- Falcone M, Tiseo G. Reply to Epling and Powers, “Cefiderocol and the need for higher-quality evidence: methods matter for patients.” *Antimicrob Agents Chemother* 2022; 66:e0079522.

32. Paterson DL, Rogers BA. How soon is now? The urgent need for randomized, controlled trials evaluating treatment of multidrug-resistant bacterial infection. *Clin Infect Dis* **2010**; 51:1245–7.
33. Inchai J, Pothirat C, Bumroongkit C, Limsukon A, Khositsakulchai W, Liwsrisakun C. Prognostic factors associated with mortality of drug-resistant *Acinetobacter baumannii* ventilator-associated pneumonia. *J Intensive Care* **2015**; 3:9.
34. Chaari A, Mnif B, Bahloul M, et al. *Acinetobacter baumannii* ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors. *Int J Infect Dis* **2013**; 17:e1225-8.
35. Robenshtok E, Paul M, Leibovici L, et al. The significance of *Acinetobacter baumannii* bacteraemia compared with *Klebsiella pneumoniae* bacteraemia: risk factors and outcomes. *J Hosp Infect* **2006**; 64:282–7.
36. Armstrong RA, Kane AD, Kursumovic E, et al. Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies. *Anaesthesia* **2021**; 76:537–48.
37. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 12.0. **2022**. Available at: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf. Accessed 6 June 2023.
38. Russo A, Gavaruzzi F, Ceccarelli G, et al. Multidrug-resistant *Acinetobacter baumannii* infections in COVID-19 patients hospitalized in intensive care unit. *Infection* **2022**; 50:83–92.
39. Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). *Intensive Care Med* **2020**; 46:854–87.
40. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ* **2021**; 372:n579.
41. Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant *Klebsiella pneumoniae* bacteraemia. *Antimicrob Agents Chemother* **2017**; 61:e00883-17.
42. Shields RK, McCreary EK, Marini RV, et al. Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections. *Clin Infect Dis* **2020**; 71:667–71.
43. Paterson DL, Kinoshita M, Baba T, Echols R, Portsmouth S. Outcomes with cefiderocol treatment in patients with bacteraemia enrolled into prospective phase 2 and phase 3 randomised clinical studies. *Infect Dis Ther* **2022**; 11: 853–70.